Physician profile
Alex A Aslan
NPI 1538115571
$1,404.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $135 · 2021: $429 · 2022: $89.92 · 2023: $295 · 2024: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.87 | 2019-2024 | Linzess, Creon, Viberzi |
| Nevro Corp. | $219.81 | 2019-2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.79 | 2019-2024 | Xifaxan |
| Ferring Pharmaceuticals INC. | $77.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.48 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $59.89 | 2021 | |
| Janssen Biotech, INC. | $55.50 | 2019-2024 | Tremfya |
| Intercept Pharmaceuticals, INC. | $51.89 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $48.28 | 2023 | Zinplava, Dificid |
| Braintree Laboratories, INC. | $45.77 | 2021-2024 | Suflave |
| Pfizer INC. | $36.17 | 2020-2021 | |
| Daiichi Sankyo INC. | $35.41 | 2021 | |
| Celgene Corporation | $13.13 | 2023 | Zeposia |
| Mauna Kea Technologies, INC. | $10.44 | 2019 | |
| Qol Medical, LLC | $4.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Aslan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.